Jose Gonzalez Chavez, MD
Dermatology · San Juan, PRNPI 1619930682
Payments from drug & device makers
Across 1,386 payments — averaging $3387.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly Export S.A. Puerto Rico Branch$2.2M
- AbbVie$1.2M
- Amgen$411K
- E.r. Squibb & Sons, L.L.C.$386K
- Eli Lilly$175K
- Sanofi$95K
- plus $216K from 23 others
Across 22 payments — averaging $2713.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$40K
- Eli Lilly Export S.A. Puerto Rico Branch$19K
What the payments were for
- Consulting fees$21,6259%
- Speaking & faculty fees$193,18478%
- Travel & lodging$9,9874%
- Food & beverage$22,1129%
- Education$7220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly Export S.A. Puerto Rico Branch | 76 | $2,227,096 |
| AbbVie | 506 | $1,185,130 |
| Amgen | 62 | $411,339 |
| E.r. Squibb & Sons, L.L.C. | 63 | $385,754 |
| Eli Lilly | 38 | $174,989 |
| Sanofi | 141 | $94,922 |
| UCB SA | 20 | $89,071 |
| Incyte Corporation | 54 | $45,545 |
| Novartis | 156 | $37,436 |
| Sanofi US Services Inc. | 2 | $21,150 |
| Lilly USA, LLC | 9 | $11,794 |
| Johnson & Johnson(2 entities) | 134 | $3,392 |
| UCB, Inc. | 13 | $3,052 |
| Bristol Myers Squibb | 4 | $1,362 |
| AstraZeneca | 18 | $618 |
| PBG Puerto Rico LLC | 24 | $499 |
| LEO Pharma Inc. | 20 | $455 |
| Sanofi-aventis U.S. LLC | 11 | $340 |
| Organon | 11 | $199 |
| Genentech, Inc. | 3 | $163 |
| Boehringer Ingelheim | 6 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Sun Pharmaceutical Industries Inc. | 4 | $85 |
| Kyowa Kirin, Inc. | 3 | $71 |
| Pfizer | 3 | $52 |
| Merck | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Pfizer Pharmaceuticals LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,694,832 in reported general payments places this provider in the 95th percentile of 108 dermatology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Unoready PenSecukinumab | 342 | $2,589,398 |
| Skyrizi PenRisankizumab-Rzaa | 79 | $1,664,288 |
| Taltz AutoinjectorIxekizumab | 190 | $1,311,169 |
| TremfyaGuselkumab | 73 | $1,018,478 |
| Dupixent SyringeDupilumab | 211 | $805,955 |
| Dupixent PenDupilumab | 172 | $673,695 |
| OtezlaApremilast | 144 | $652,396 |
| Humira(Cf) PenAdalimumab | 72 | $634,885 |
| StelaraUstekinumab | 27 | $514,406 |
| RinvoqUpadacitinib | 26 | $167,324 |
| Taltz Autoinjector (2 Pack)Ixekizumab | 11 | $147,428 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 20 | $146,475 |
| Enbrel SureclickEtanercept | 20 | $143,251 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 33 | $87,510 |
| Bexarotene | 16 | $18,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya, Stelara | $3,392 | $1,532,883100 claims |
| AmgenOtezla | $411,339 | $652,396144 claims |
| AbbVieRinvoq | $1,185,130 | $167,32426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 dermatology providers in Puerto Rico.
Other dermatology in San Juan
- Maria Martinez ColonSan Juan$1.4M
- Rafael Martin GarciaSan Juan$199K
- Noelani Gonzalez-OrtizSan Juan$154K
- Elena Montalvan MiroSan Juan$20K
- Damaris Torres PaoliSan Juan$6K
- Natalia Pelet del ToroSan Juan$5K
- Frances HernandezSan Juan$5K
- Karina Cancel ArtauSan Juan$4K
- Eduardo Michelen GomezSan Juan$4K
- Andrea CaroSan Juan$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.